Elicio Therapeutics (NASDAQ:ELTX) Releases Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Elicio Therapeutics (NASDAQ:ELTX) posted its quarterly earnings results on Monday. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16), FiscalAI reports.

Elicio Therapeutics Price Performance

Shares of Elicio Therapeutics stock traded up $1.70 on Monday, hitting $11.61. The company’s stock had a trading volume of 328,155 shares, compared to its average volume of 131,412. The company has a market capitalization of $217.11 million, a P/E ratio of -4.43 and a beta of 1.12. Elicio Therapeutics has a 52-week low of $5.15 and a 52-week high of $14.93. The firm has a fifty day moving average price of $11.37 and a 200-day moving average price of $9.51. The company has a quick ratio of 2.38, a current ratio of 2.38 and a debt-to-equity ratio of 5.75.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ELTX shares. Rodman & Renshaw upgraded shares of Elicio Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Wall Street Zen raised shares of Elicio Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Friday, April 24th. HC Wainwright increased their target price on shares of Elicio Therapeutics from $13.00 to $17.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, LADENBURG THALM/SH SH assumed coverage on Elicio Therapeutics in a research note on Wednesday, April 15th. They set a “buy” rating and a $20.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Quadrature Capital Ltd purchased a new stake in Elicio Therapeutics in the 4th quarter valued at approximately $137,000. Occudo Quantitative Strategies LP purchased a new position in Elicio Therapeutics during the fourth quarter worth $126,000. 683 Capital Management LLC acquired a new position in shares of Elicio Therapeutics in the fourth quarter worth $449,000. Squarepoint Ops LLC purchased a new stake in shares of Elicio Therapeutics in the fourth quarter valued at $133,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Elicio Therapeutics during the fourth quarter valued at $187,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.